Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Laser fibre, rather than the stone, may harm the scope: retrospective monocentric analysis of 26 pre- and intraoperative factors of flexible ureteroscope (fURS) damage.

Ozimek T, Cordes J, Gilbert N, Hupe MC, Wiessmeyer JR, Schneider MH, Merseburger AS, Kramer MW.

World J Urol. 2019 Oct 28. doi: 10.1007/s00345-019-02988-0. [Epub ahead of print]

PMID:
31659464
2.

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.

Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN; TITAN investigators.

Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.

PMID:
31578173
3.

[Rate of thrombosis and bleeding after urological surgery under standardized anticoagulation].

Morische SK, Kramer MW, Merseburger AS, Gieseler F, Cordes J.

Urologe A. 2019 Sep 20. doi: 10.1007/s00120-019-01045-3. [Epub ahead of print] German.

PMID:
31541268
4.

[Current recommendations for the systemic treatment of metastatic renal cell carcinoma].

Kröger N, Merseburger AS, Bedke J.

Aktuelle Urol. 2019 Sep 4. doi: 10.1055/a-0972-0788. [Epub ahead of print] German.

PMID:
31486060
5.

Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2019 Sep 3;9(1):12864. doi: 10.1038/s41598-019-49304-9.

6.

[Status quo 5 years after the introduction of the new ISUP 2014/WHO 2016 prostate cancer grade groups].

Hupe MC, Offermann A, Sailer V, Merseburger AS, Perner S.

Aktuelle Urol. 2019 Aug 7. doi: 10.1055/a-0918-9473. [Epub ahead of print] German.

PMID:
31390661
7.

[Molecular tumor board in uro-oncology].

Kübler H, Merseburger AS.

Urologe A. 2019 Jul;58(7):745-746. doi: 10.1007/s00120-019-0978-2. German. No abstract available.

PMID:
31292704
8.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Int J Cancer. 2019 Jul 4. doi: 10.1002/ijc.32551. [Epub ahead of print]

PMID:
31271443
9.

Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study.

Attard G, Merseburger AS, Arlt W, Sternberg CN, Feyerabend S, Berruti A, Joniau S, Géczi L, Lefresne F, Lahaye M, Shelby FN, Pissart G, Chua S, Jones RJ, Tombal B.

JAMA Oncol. 2019 Jun 27. doi: 10.1001/jamaoncol.2019.1011. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Aug 1;5(8):1232.

10.

TRIM24 as an independent prognostic biomarker for prostate cancer.

Offermann A, Roth D, Hupe MC, Hohensteiner S, Becker F, Joerg V, Carlsson J, Kuempers C, Ribbat-Idel J, Tharun L, Sailer V, Kirfel J, Svensson M, Andren O, Lubczyk V, Kuefer R, Merseburger AS, Perner S.

Urol Oncol. 2019 Sep;37(9):576.e1-576.e10. doi: 10.1016/j.urolonc.2019.05.006. Epub 2019 Jun 7.

PMID:
31178279
11.

Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel.

Fernández-Pello S, Hora M, Kuusk T, Tahbaz R, Dabestani S, Abu-Ghanem Y, Albiges L, Giles RH, Hofmann F, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A, Bensalah K.

Eur Urol Oncol. 2019 Jun 3. pii: S2588-9311(19)30054-9. doi: 10.1016/j.euo.2019.04.005. [Epub ahead of print] Review.

PMID:
31171501
12.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fernández-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A.

Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.

PMID:
31151678
13.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S; TITAN Investigators.

N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.

PMID:
31150574
14.

Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA.

Morera DS, Lahorewala SS, Belew D, Ghosh S, Klaassen Z, Jordan AR, Wang J, Terris MK, Bollag RJ, Merseburger AS, Stenzl A, Soloway MS, Lokeshwar VB.

J Urol. 2019 May 21:101097JU0000000000000351. doi: 10.1097/JU.0000000000000351. [Epub ahead of print]

PMID:
31112107
15.

CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.

Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J.

Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16.

PMID:
31092909
16.

The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature.

Offermann A, Hupe MC, Sailer V, Merseburger AS, Perner S.

World J Urol. 2019 Apr 2. doi: 10.1007/s00345-019-02744-4. [Epub ahead of print] Review.

PMID:
30941561
17.

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS.

Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

18.

Anti-Amphiphysin-associated limbic encephalitis in a 72-year-old patient with aortic angiosarcoma.

Wagner-Altendorf TA, Wandinger KP, Frydrychowicz A, Merseburger AS, Münte TF.

BMJ Case Rep. 2019 Mar 14;12(3). pii: e226798. doi: 10.1136/bcr-2018-226798.

PMID:
30872337
19.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A.

Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.

PMID:
30803729
20.

β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.

Kallifatidis G, Smith DK, Morera DS, Gao J, Hennig MJ, Hoy JJ, Pearce RF, Dabke IR, Li J, Merseburger AS, Kuczyk MA, Lokeshwar VB, Lokeshwar BL.

Mol Cancer Ther. 2019 Apr;18(4):801-811. doi: 10.1158/1535-7163.MCT-18-1167. Epub 2019 Feb 20.

PMID:
30787175
21.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

22.

Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes.

Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS.

Front Oncol. 2018 Nov 27;8:543. doi: 10.3389/fonc.2018.00543. eCollection 2018.

23.

Imaging in Suspected Renal-Cell Carcinoma: Systematic Review.

Vogel C, Ziegelmüller B, Ljungberg B, Bensalah K, Bex A, Canfield S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Albiges L, Stewart F, Volpe A, Graser A, Schlemmer M, Yuan C, Lam T, Staehler M.

Clin Genitourin Cancer. 2019 Apr;17(2):e345-e355. doi: 10.1016/j.clgc.2018.07.024. Epub 2018 Aug 11.

PMID:
30528378
24.

Transient increased tumescence of the glans penis during penile erection after endovenous ablation of the great saphenous vein.

Cordes J, Zimbelmann M, Merseburger AS, Kramer M, Vonthein R, Büttner H, Recke A, Kahle BK.

J Vasc Surg Venous Lymphat Disord. 2019 May;7(3):387-391. doi: 10.1016/j.jvsv.2018.06.014. Epub 2018 Nov 23.

PMID:
30477979
25.

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.

Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN.

World J Urol. 2019 Jan;37(1):95-105. doi: 10.1007/s00345-018-2486-1. Epub 2018 Sep 20. Review.

PMID:
30238401
26.

Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).

Nicklas AP, Kramer MW, Serth J, Hennenlotter J, Hupe MC, Reimer DU, Stenzl A, Merseburger AS, Kuczyk MA, von Klot CJ.

Adv Ther. 2018 Nov;35(11):2054-2068. doi: 10.1007/s12325-018-0789-7. Epub 2018 Sep 19.

27.

Extended Techniques of Minimally Invasive Surgery in the Retroperitoneum: Practice Pattern in German Urology Departments.

Hupe MC, Kramer MW, Ozimek T, Merseburger AS, Imkamp F.

Urol Int. 2018;101(3):345-350. doi: 10.1159/000493148. Epub 2018 Sep 18.

PMID:
30227439
28.

A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.

Bex A, Albiges L, Staehler M, Bensalah K, Giles RH, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Volpe A, Ljungberg B, Escudier B, Powles T.

Eur Urol. 2018 Dec;74(6):849-851. doi: 10.1016/j.eururo.2018.08.029. Epub 2018 Sep 7. No abstract available.

PMID:
30201510
29.

[Symptomatic renal tumours in metastatic renal cell carcinoma - surgical options].

Gilbert N, Merseburger AS, Kramer M.

Aktuelle Urol. 2018 Sep;49(5):417-421. doi: 10.1055/a-0658-0832. Epub 2018 Sep 5. German.

PMID:
30184600
30.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Abu-Ghanem Y, Staehler M, Volpe A, Powles T.

Eur Urol. 2018 Dec;74(6):805-809. doi: 10.1016/j.eururo.2018.08.008. Epub 2018 Aug 31.

PMID:
30177291
31.

Promise and Implementation of Proteomic Prostate Cancer Biomarkers.

Latosinska A, Frantzi M, Merseburger AS, Mischak H.

Diagnostics (Basel). 2018 Aug 29;8(3). pii: E57. doi: 10.3390/diagnostics8030057. Review.

32.

[Practice Pattern of Systemic Therapy for Urothelial Cancer in Germany - A Survey of the German Cancer Society].

Hupe MC, Merseburger AS, de Wit M, Rexer H, Gschwend JE, Krege S.

Aktuelle Urol. 2018 Aug;49(4):346-354. doi: 10.1055/a-0645-1076. Epub 2018 Aug 7. German.

PMID:
30086593
33.

A New Automatically Fixating Stone Basket (2.5 F) Prototype with a Nitinol Spring for Accurate Ureteroscopic Stone Size Measurement.

Cordes J, Nguyen F, Pinkowski W, Merseburger AS, Ozimek T.

Adv Ther. 2018 Sep;35(9):1420-1425. doi: 10.1007/s12325-018-0761-6. Epub 2018 Aug 4.

34.

The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells.

Hupe MC, Hoda MR, Zengerling F, Perner S, Merseburger AS, Cronauer MV.

World J Urol. 2019 Feb;37(2):343-349. doi: 10.1007/s00345-018-2382-8. Epub 2018 Jun 22.

PMID:
29934670
35.

Steep Infundibulopelvic Angle as a New Risk Factor for Flexible Ureteroscope Damage and Complicated Postoperative Course.

Ozimek T, Cordes J, Wiessmeyer JR, Schneider MH, Hupe MC, Gilbert N, Merseburger AS, Kramer MW.

J Endourol. 2018 Jul;32(7):597-602. doi: 10.1089/end.2018.0147. Epub 2018 Jun 7.

PMID:
29737199
36.

Urinary CE-MS peptide marker pattern for detection of solid tumors.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Sci Rep. 2018 Mar 27;8(1):5227. doi: 10.1038/s41598-018-23585-y. Erratum in: Sci Rep. 2019 Sep 3;9(1):12864.

37.

Substantial utilization of Facebook, Twitter, YouTube, and Instagram in the prostate cancer community.

Struck JP, Siegel F, Kramer MW, Tsaur I, Heidenreich A, Haferkamp A, Merseburger AS, Salem J, Borgmann H.

World J Urol. 2018 Aug;36(8):1241-1246. doi: 10.1007/s00345-018-2254-2. Epub 2018 Mar 9.

PMID:
29523948
38.

Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.

Dogan S, Hennig M, Frank T, Struck JP, Cebulla A, Salem J, Borgmann H, Klatte T, Merseburger AS, Kramer M, Hofbauer SL.

Urol Int. 2018;101(1):25-30. doi: 10.1159/000487405. Epub 2018 Mar 6.

PMID:
29510388
39.

Diarrhea and flatulence are major bowel disorders after radical cystectomy: Results from a cross-sectional study in bladder cancer patients.

Hupe MC, Vahlensieck W, Ozimek T, Struck JP, Hennig MJP, Tezval H, von Klot CA, Merseburger AS, Kuczyk MA, Kramer MW.

Urol Oncol. 2018 May;36(5):237.e1-237.e8. doi: 10.1016/j.urolonc.2017.12.014. Epub 2018 Feb 1.

PMID:
29395950
40.

[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].

Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV.

Aktuelle Urol. 2018 Jan 25. doi: 10.1055/s-0043-115426. [Epub ahead of print] German.

PMID:
29370587
41.

Rho GDP dissociation inhibitor-β in renal cell carcinoma.

von Klot CA, Dubrowinskaja N, Peters I, Hennenlotter J, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

Oncol Lett. 2017 Dec;14(6):8190-8196. doi: 10.3892/ol.2017.7233. Epub 2017 Oct 20.

42.

68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer.

von Klot CJ, Merseburger AS, Böker A, Schmuck S, Ross TL, Bengel FM, Kuczyk MA, Henkenberens C, Christiansen H, Wester HJ, Solass W, Lafos M, Derlin T.

Nucl Med Mol Imaging. 2017 Dec;51(4):314-322. doi: 10.1007/s13139-017-0476-7. Epub 2017 Mar 7.

43.

Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.

Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-Pello S, Tahbaz R, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2017 Dec 7. pii: S0302-2838(17)31001-1. doi: 10.1016/j.eururo.2017.11.016. [Epub ahead of print]

PMID:
29223605
44.

[Inhibitors of the androgen receptor N‑terminal domain : Therapies targeting the Achilles' heel of various androgen receptor molecules in advanced prostate cancer].

Hupe MC, Offermann A, Perabo F, Chandhasin C, Perner S, Merseburger AS, Cronauer MV.

Urologe A. 2018 Feb;57(2):148-154. doi: 10.1007/s00120-017-0541-y. Review. German.

PMID:
29147733
45.

Retrospective Cost Analysis of a Single-Center Reusable Flexible Ureterorenoscopy Program: A Comparative Cost Simulation of Disposable fURS as an Alternative.

Ozimek T, Schneider MH, Hupe MC, Wiessmeyer JR, Cordes J, Chlosta PL, Merseburger AS, Kramer MW.

J Endourol. 2017 Dec;31(12):1226-1230. doi: 10.1089/end.2017.0427. Epub 2017 Nov 17.

PMID:
29073769
46.

Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition.

Tahbaz R, Schmid M, Merseburger AS.

Curr Opin Urol. 2018 Jan;28(1):62-79. doi: 10.1097/MOU.0000000000000454. Review.

PMID:
29059103
47.

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention.

Latosinska A, Mokou M, Makridakis M, Mullen W, Zoidakis J, Lygirou V, Frantzi M, Katafigiotis I, Stravodimos K, Hupe MC, Dobrzynski M, Kolch W, Merseburger AS, Mischak H, Roubelakis MG, Vlahou A.

Oncotarget. 2017 Apr 20;8(41):69435-69455. doi: 10.18632/oncotarget.17279. eCollection 2017 Sep 19.

48.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

49.

Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.

Latosinska A, Frantzi M, Vlahou A, Merseburger AS, Mischak H.

Proteomics Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700074. Epub 2017 Oct 25. Review.

PMID:
28980455
50.

Hyaluronic acid family in bladder cancer: potential prognostic biomarkers and therapeutic targets.

Morera DS, Hennig MS, Talukder A, Lokeshwar SD, Wang J, Garcia-Roig M, Ortiz N, Yates TJ, Lopez LE, Kallifatidis G, Kramer MW, Jordan AR, Merseburger AS, Manoharan M, Soloway MS, Terris MK, Lokeshwar VB.

Br J Cancer. 2017 Nov 7;117(10):1507-1517. doi: 10.1038/bjc.2017.318. Epub 2017 Oct 3.

Supplemental Content

Loading ...
Support Center